The company
Cadrenal Therapeutics, Inc.
CVKD · Nasdaq
CVKD stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 67.6% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 52
- Industry in uptrend
- 18% -14 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $930K
- Officials’ trades on record
- 0
- Institutions holding
- 16 (+1)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Quang X. PhamChairman and CEO | sold | 7,400at $3.03 | 29 Jun 2026filed 1 Jul 2026 |
| Quang X. PhamChairman, CEO and Interim CFO | sold | 9,029at $3.05 | 26 Jun 2026filed 26 Jun 2026 |
| Quang X. PhamChairman, CEO and Interim CFO | sold | 2,127at $3.00 | 25 Jun 2026filed 26 Jun 2026 |
| Quang X. PhamChairman, CEO and Interim CFO | sold | 2,277at $3.20 | 23 Jun 2026filed 24 Jun 2026 |
| Quang X. PhamChairman, CEO and Interim CFO | sold | 9,167at $3.55 | 22 Jun 2026filed 24 Jun 2026 |
| Quang X. PhamChairman, CEO and Interim CFO | sold | 513at $3.16 | 17 Jun 2026filed 18 Jun 2026 |
| Quang X. PhamChairman, CEO and Interim CFO | sold | 3,613at $3.18 | 16 Jun 2026filed 18 Jun 2026 |
| Quang X. PhamChairman, CEO and Interim CFO | sold | 3,666at $3.58 | 15 Jun 2026filed 15 Jun 2026 |
| Quang X. PhamChairman, CEO and Interim CFO | sold | 12,996at $3.94 | 12 Jun 2026filed 15 Jun 2026 |
| Quang X. PhamChairman, CEO and Interim CFO | sold | 1,462at $4.12 | 11 Jun 2026filed 15 Jun 2026 |
| Quang X. PhamChairman, CEO and Interim CFO | sold | 3,500at $4.21 | 10 Jun 2026filed 10 Jun 2026 |
| Quang X. PhamChairman, CEO and Interim CFO | sold | 12,992at $4.06 | 9 Jun 2026filed 10 Jun 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 50,137$167K | +4,936+10.9% |
| GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026 | 19,024$64K | -2,602−12.0% |
| VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 2026 | 8,311$28K | 00.0% |
| Tower Research Capital LLC (TRC)added · filed 11 Aug 2026 | 1,282$4,282 | +889+226.2% |
| UBS Group AGadded · filed 13 Aug 2026 | 1,112$3,714 | +1,109+36966.7% |
| Grove Bank & Trustnew · filed 7 Jul 2026 | 1,000$3,340 | +1,000 |
| MORGAN STANLEYadded · filed 13 Aug 2026 | 706$2,358 | +606+606.0% |
| Clearstead Advisors, LLCnew · filed 6 Aug 2026 | 650$2,171 | +650 |
| Quest 10 Wealth Builders, Inc.new · filed 24 Jul 2026 | 380$1,269 | +380 |
| OSAIC HOLDINGS, INC.unchanged · filed 14 Aug 2026 | 300$1,002 | 00.0% |
News
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.